Product Description
Firibastat, a first-in-class drug candidate for resistant hypertension. The firibastat product is a prodrug that delivers in the brain the EC33 product, a selective and specific inhibitor of Aminopeptidase A, thus preventing the production of Angiontensin III in the brain. (Sourced from: https://quantum-genomics.com/en/science/pipeline/firibastat-first-in-class-hypertension-as-monotherapy/)
Mechanisms of Action: APA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Quantum Genomics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic, France, Germany, Poland, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Hypertension|Resistant Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Firibastat in treatment-RESistant Hypertension (FRESH) | P3 |
Completed |
Resistant Hypertension |
2022-09-20 |
|
| FRESH | P3 |
Completed |
Hypertension |
2022-08-30 |
90% |